We invest in entrepreneurs with the ambition to create world-class companies of scale.

Gerry is a General Partner at Atlantic Bridge and is an experienced Investor, Executive and Design Engineer with a thirty-year career in the technology industry. Prior to joining Atlantic Bridge, he was Vice President R&D at Parthus Technologies responsible for managing a business which included divisions in Ireland, UK and USA. Gerry joined the company in 1993 and played a key role in its transition from startup to successful IPO on Nasdaq. Gerry also held senior management roles at several technology companies including Philips and Texas Instruments. Gerry has a BA, BAI degree in Electronic Engineering from Trinity College Dublin and a Diploma in Company Direction from the Institute of Directors.

Helen joined Atlantic Bridge in 2015 on our University Bridge Fund. At Atlantic Bridge, Helen leads investing in early stage deeptech companies.
With a strong track record built over 15 years, Helen has successfully sourced and financed over 40 deep tech ventures including notable Irish companies: Neurent Medical, Equal1, Siren, Output Sports, Proverum Medical, Plasmabound and Manna. Companies from Atlantic Bridge’s early stage portfolio have to date raised over €700m and continue to grow and scale globally.
Helen is on the board of many venture backed companies and chairs the Governance Committee of IPIC , a Science Foundation Ireland Centre for photonics. Helen is both mentor and advisor to organisations including Knowledge Transfer Ireland, IVCA, UCD VentureLaunch, Start100 and is a prior VP at TechTour.
Passionate about encouraging young people’s involvement in STEM, Helen is board member of the education focused non-profit, Kinia, and is a judge at the BT Young Scientist and Technology Competition.
Helen is listed as one of the Top 100 Women in STEM in Ireland and is a Kauffman Fellow. Helen was awarded a 1st Class Hons. Electronic Engineering Degree (UCD) and a PhD (The University of Edinburgh) in the area of AI based conversational agents and multimodal interfaces.

Conor joined Atlantic Bridge in 2021 where he focuses on identifying and evaluating new investment opportunities for the University Bridge Funds.
Prior to joining Atlantic Bridge, Conor was based in London where he was Vice President at Paladin Capital, one of the most active early-stage venture capital investors in the cybersecurity sector. Before Paladin Conor was Investment Manager at Seraphim Capital, the largest investment group dedicated to investing in space technology start-ups.
Following his MBA at the University of Oxford, Conor joined the Satellite Applications Catapult, a space research and technology centre funded by the UK Government, as Head of Business Strategy supporting over 100 start-ups. Prior to this Conor worked in sales, trading and operational roles for 5 years at two global investment banks.
Conor holds an MBA from the University of Oxford and a BA in Business and Economics from Trinity College Dublin.

Dominik joined Atlantic Bridge as a Senior Investment Associate on the University Bridge Fund in 2022. Prior to joining Atlantic Bridge, Dominik was an Investment Manager in the Life Science Team of the University College London (UCL) Technology Fund which is managed by Albion Capital. Before joining the UCL Technology Fund, Dominik was responsible for the commercialisation of technologies that originated at the UCL Cancer Institute and the UCL GOSH Institute of Child Health. He has also held different R&D roles within the medical device and speciality pharmaceutical industries. Dominik holds a BSc in Life Sciences Technologies from the University of Northern Switzerland and a MSc in Innovation and Management from Imperial College Business School.

Weili joined the University Bridge Fund in 2021. Prior to joining Atlantic Bridge, Weili was a Biotech Investment Fellow at M Ventures, the venture capital arm of Merck KGaA. Before entering the venture capital world, Weili gained experienced across roles in the University of Queensland Technology Transfer Office, KPMG, as well as in Independent Innovation Centres. Weili holds two Master's degrees in Molecular Biology & Technology and Innovation Management, as well as a PhD in Molecular Biology from the University of Queensland.

Helen Ryan was the Chief Executive Officer of Creganna-Tactx Medical from 2005 until September 2013. Creganna-Tactx Medical is a global supplier to the medical device industry specialising in products, technologies and solutions for minimally invasive therapies. The company is currently ranked among the world’s top 10 medical device outsource providers. During Helen’s time as CEO, the company grew five-fold to become the largest indigenous medical device company. The expansion included three company acquisitions, a strategic joint venture in Asia, and the raising of significant debt and equity financing. The organisation grew from 100 people at a single site in Galway to over 1,250 people across a global network of four sites in Ireland, the USA and Singapore. Prior to joining Creganna-Tactx in 2003, Helen worked with Medtronic and Tyco Healthcare (Covidien) in Product Development and R&D functional management roles. Helen has a Bachelor of Engineering from NUI Galway, a Masters in Project Management from UL, and has completed a Senior Executive Programme at Stanford University. Helen is a fellow of the Institute of Engineers of Ireland, a past Chair of the Irish Medical Devices Association, and serves as a non-executive director of a number of companies.

Dr. Westrup is the Director of Oncology, and a Consultant Medical Oncologist at Beacon Hospital Dr. Westrup is appointed Associate Clinical Professor at University College Dublin and sits on the steering committee of the innovative UCD Beacon Academy. Dr. Westrup is the former Medical Director at Beacon Hospital. Dr. Westrup was a member of the original Beacon Hospital Board from 2007 – 2008, served as Chairperson of the Beacon Pharmacy/Therapeutics Committee for 3 years, and as the Director of Education for Beacon Hospital from 2008 – 2014. She currently sits on the Clinical Governance Committee of the Beacon Hospital Board, and was an invited member of the International Quality and Patient Safety Committee of UPMC. Dr. Westrup lectures on the UCD Risk Management Program. Dr. Westrup is a member of Cancer Trials Ireland. Her past research on breast cancer has been presented at international conferences, and is published in peer reviewed journals. Dr. Westrup currently advises the Health Care Products Regulatory Clinical Sub Trials Committee. She is a member of the National Cancer Care Program, Melanoma Clinical Advisory Group. Dr. Westrup graduated Cum Laude from Wake Forest University with a BSc in Biology and received her medical degree with honours at University College Dublin. She completed an Internal Medicine Residency at Boston University Medical Center, was Resident Teacher of the Year and awarded the CREST scholarship; a National Institute of Health Grant. She completed a fellowship in Hematology/Oncology at Boston University Medical Center and was honoured as Chief Fellow. Dr. Westrup is American Board Certified in Internal Medicine and Medical Oncology.

Brendan Cremen has an engineering background and has been active in technology and business innovation throughout his career. In the 1980s, he was a member of the start-up team at Lattice Semiconductor in the US and held senior engineering and business management roles there through to IPO. On returning to Ireland in the mid-1990s, Brendan joined the launch team for Xilinx Ireland where he led the expansion of its mandate as an international R&D hub for the corporation. More recently, he spent 10 years in the development of the commercialisation agenda within the Irish university sector, most directly with UCC and UCD. At UCD he drove the establishment of the University Bridge Fund and now is an advisor to this fund.

John Hearne joined Atlantic Bridge as a senior strategic advisor and investor in 2016. John co-founded Cúram (provider of software to help government agencies administer social welfare and health services) which was acquired by IBM in 2011. He served as Cúram Software’s CEO, successfully overseeing its growth into one of the leading providers of HR & GovTech Software. Expertise in enterprise software, GovTech, SaaS & scaling.

Carl Jackson has an Electronics Engineering background, completing a PhD after immigrating to Ireland in the late 90s. Carl spun-out the semiconductor sensor technology from his PhD into SensL promptly spending the next 14 years building a fantastic team, products and brand to become the leading sensor supplier in markets from medical imaging to automotive. SensL was purchased by Onsemi in 2018. Carl was VP Engineering at Onsemi for 3 years before exiting the business to focus on startups as an entrepreneur. Carl currently engages with an exciting group of startups and SMEs investing, advising and as an active participant as needed to assist each in moving forward rapidly to build shareholder value and realize their full potential. Carl has strategically advised companies from founding, funding, growing, operating to exiting. In Carl's last exit in 2023 he operated as banker and seller's rep, realizing the sale of the high tech start-up to that industry's NASDAQ listed market leader. Carl works with Atlantic Bridge as Strategic Advisor from his home base in Cork particularly involved with his alma mater, UCC and Tyndall to encourage the next generation of spin-outs.